Intellectual property and chirality of drugs

Drug Discovery Today

Volumn 4, Issue 7, 1999, Pages 313-321

  Agranat, Israel ^a   Caner, Hava ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; AMOXICILLIN; BENZOMORPHAN DERIVATIVE; DESFLURANE; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; IBUPROFEN; INSECTICIDE; ISOFLURANE; MORPHINE; OMEPRAZOLE; PROPIONIC ACID DERIVATIVE;

CHIRALITY; DECISION MAKING; DRUG DESIGN; ENANTIOMER; FOOD AND DRUG ADMINISTRATION; ISOMER; PATENT; REVIEW; STEREOCHEMISTRY;

EID: 0033167950     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(99)01363-X     Document Type: Review

References (67)

1. 1 Crossley, R. (1995) Chirality and the Biological Activity of Drugs, CRC Press
2. 2 Aboul-Enein, H.Y. and Wainer, I.W., eds (1997) The Impact of Stereochemistry on Drug Development and Use (Chemical Analysis Vol. 142), Wiley
3. 3 Eichelbaum, M. and Gross, A.S. (1996) Adv. Drug Res. 28, 1-64
4. 4 Crossley, R. (1992) Tetrahedron 48, 8155-8178
5. 5 Stinson, S.C. (1997) Chem. Eng. News 75(42), 38-70
6. 6 Stinson, S.C. (1998) Chem. Eng. News 76(38), 83-104
7. 7 Richards, A. and McCague, R. (1996) Chem. Ind. 11, 422-425
8. 8 Van Eikeren, P. (1996) in Chiral Separations: Applications and Technology (Ahuja, S., ed.), pp. 9-35, American Chemical Society
9. 9 Carey, J. (1993) Chem. Br. 29, 1053-1056
10. 10 FDA's Policy Statement on the Development of New Stereoisomeric Drugs (Stereisomeric Drug Policy) Fed. Regist. (1992) 57 FR22249
11. 11 Committee for Proprietary Medicinal Products. Working Parties on Quality, Safety and Efficacy of Medicinal Products (1993) Note for Guidance: Investigation of Chiral Active Substances, III/3501/91
12. 12 Crosby, J. (1997) in Chirality in Industry II. Developments in the Commercial Manufacture and Application of Optically Active Compounds (Collins, A.N., Sheldrake, G.N. and Crosby, J., eds), pp. 1-10, Wiley
13. 13 Daniels, J.M., Nestmann, E.R. and Kerr, A. (1997) Drug Inf. J. 31, 639-646
14. 14 Blumenstein, J.J. (1997) in Chirality in Industry II. Developments in the Commercial Manufacture and Application of Optically Active Compounds (Collins, A.N., Sheldrake, G.N. and Crosby, J., eds), pp. 11-18, Wiley
15. 15 Shindo, H. and Caldwell, J. (1995) Chirality 7, 349-352
16. 16 Bainbridge, D.I. (1994) Intellectual Property (2nd edn), pp. 3-7, Pitman
17. 17 Harmon, R.L. (1994) Patents and the Federal Circuit (3rd edn), p. 8, BNA Books
18. 18 Kaba, R.A., Crossman, D.A. and Tabin, J. (1995) Burger's Medicinal Chemistry and Drug Discovery (Vol. 1, 5th edn) (Wolf, M.E., ed.), pp. 37-102, Wiley
19. 19 Grubb, P.W. (1987) Annual Reports in Medicinal Chemistry (Vol. 22) (Bailey, D.M., ed.), pp. 331-352, Academic Press
20. 20 Grubb, P.W. (1986) Patents in Chemistry and Biotechnology, Oxford University Press
21. 21 Vieillefosse, J-C. (1990) Comprehensive Medicinal Chemistry (Vol. 1) (Kennewell, P.D., ed.), pp. 675-698, Pergamon Press
22. 22 Patent and Trademark Laws (1989) The Bureau of National Affairs Washington, DC
23. 23 Public Law 98-417, Drug Price Competition and Patent Term Restoration Act, Amendment of the Federal Food, Drug and Cosmetic Act (Hatch-Waxman Amendment)
24. 24 European Patent Convention (1977) European Patent Office, Munich
25. 25 Blanco White, T.A. (1983) Patents for Inventions (5th edn), pp. 61-64 and pp. 107-111, Stevens & Sons
26. 26 I.G. Farbenindustrie (1930) 47 RPC 289-341
27. 27 DuPont (Witsiepe) (1982) FRS 303-316 (H.L.)
28. 28 Bayer (Boatz) (1982) RPC 319-324 (EPO/TBA)
29. 29 ICI's Application No. 1069343 (1971) opposed by Sandoz, PAT unreported (quoted in Ref. 25, p. 61)
30. 30 Re Dillon (1990) 919F.2d 68, 16 USPQ 692-693
31. 31 Beecham Group Limited's (Amoxicillin) Application (1980) RPC 261-304 (CA)
32. 32 Re Adamson and Duffin (1960) 47 US CCPA 841, 125 USPQ 233
33. 33 Re May and Eddy (1978) US CCPA 574F.2d 1082, 197 USPQ 601
34. 34 Re Williams (1948) 36 US CCPA 756,171,F.2d 319, 80 USPQ 150
35. 35 Re Albrecht (1975) US CCPA 1975, 514F. 2d 1389, 185 USPQ 585,590
36. 36 Enantiomers/Hoechst EPO/TBA (1990) T296/87 (1988); OJ EPO 195
37. 36 Enantiomers/Hoechst EPO/TBA (1990) T296/87 (1988); OJ EPO 195
38. 37 Erythro-compounds/Novartis EPO/TBA (1998) T990/96 (1998); OJ EPO 21, 467 (European Patent Application No. 93106005.7, Publication No. 0562643)
39. 37 Erythro-compounds/Novartis EPO/TBA (1998) T990/96 (1998); OJ EPO 21, 467 (European Patent Application No. 93106005.7, Publication No. 0562643)
40. 38 Halpern, D.F. (1993) Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications (Studies in Organic Chemistry 48) (Filler, R., Kobayashi, Y. and Yagupolski, L.M., eds), pp. 101-133, Elsevier
41. 39 Biedermann, P.U. et al. (1999) J. Chem. Org. 64, 3878-3884
42. 40 Young, J.W. and Brandt, S. (Sepracor Inc.) (1992) US 5114714
43. 41 Young, J.W. and Brandt, S. (Sepracor Inc.) (1992) US 5114715
44. 42 Tetra Molectric Ltd's Application (1977) RPC 290-297
45. 43 Eliel, E.L., Wilen, S.H. and Mander, L.N. (1994) Stereochemistry of Organic Compounds, p. 154, Wiley
46. 44 Hunt, A.J. and Caldwell, J. (1983) J. Pharm. Pharmacol. 35, 693-704
47. 45 Mayer, J.M. and Testa, B. (1997) Drugs Future 22, 1347-1367
48. 46 Sunshine, A. and Laska, E.M. (Sterling Winthrop Inc.) (1994) EP 0324007 B1
49. 47 Decision of the Opposition Division EPO (1997) revoking EP 0324007 B1
50. 48 Baldessarini, R.J. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics (9th eds) (Hardman, J.G. and Limbird, L.E., eds-in-chief), pp. 431-459, McGraw-Hill
51. 49 Robertson, D.W. et al. (1988) J. Med. Chem. 31, 1412-1417
52. 50 Young, J.W. and Berberich, T.J. (Sepracor Inc.) (1996) US 5589511
53. 51 Young, J.W., Berberich, T.J. and Teicher, M.H. (Sepracor Inc.) (1997) US 5648396
54. 52 Fuller, R.W. et al. (Eli Lilly and Company) (1993) US 5250571
55. 53 Robertson, D.W. and Wong, D.T. (Eli Lilly and Company) (1993) US 5250572
56. 54 Robertson, D.W. and Wong, D.T. (Eli Lilly and Company) (1994) US 5356934
57. 55 Rogers, R.S. (1998) Chem. Eng. News 76(48), 11-13
58. 56 SCRIP (1998) 2395, 8
59. 57 Brunton, L.L. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics (9th edn) (Hardman, J.G. and Limbird, L.E., eds-in-chief), pp. 901-915, McGraw-Hill
60. 58 Von Unge, S., Langer, V. and Sjölin, L. (1997) Tetrahedron Asymmetry 8, 1967-1970
61. 59 Lindberg, P.L. and Von Unge, S. (Astra Aktbolag) (1998) US 5714504
62. 60 Graham, D. et al. (Astra Aktbolag) (1998) US 5776765
63. 61 Astra Aktbolag (1997) Omeprazole-The Proven Partner for Comprehensive Management of Acid-NSAID Disease, pp. 1-28, Caudex Medical
64. 62 Fed. Regist. (1997) 62, 62890-62910
65. 63 SCRIP (1996) 2191, 19
66. 64 US Department of Health and Human Services (1997) Morbidity and Mortality Weekly Report 46(45), 1061-1066
67. 65 Lloyd, A.W. (1997) Drug Discovery Today 2, 127